Lightnews — Scholar-powered news

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 24d

Mackenzie Bourke presented “Incorporating individual-level preferences into cost-effectiveness analysis of population genomic risk screening: a discrete event simulation.”

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 24d

Lizzy Liu presented “Risk in preferences for breast cancer genomic risk screening and subsequent prevention protocols.”

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 24d

Julia Steinberg presented “Community preferences for population-wide genomic risk stratification (using polygenic risk scores) and risk-tailored cancer screening.”

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · 24d

Last week, Lizzy Liu and Mackenzie Bourke presented in an organised session at the AHES Conference in Canberra on the value of population-wide genomic risk assessment for cancer screening, alongside A/Prof Julia Steinberg from the Daffodil Centre.

1

Reposted by Economics of Genomics and Precision Medicine Unit

IHEA Econ-Omics SIG @ihea-econ-omics.bsky.social · Aug 14

(1/4) INVITATION: Applying #MendelianRandomization in #HealthEconomics - Bridging #Genomics & #CostEffectiveness

🗓️ Tues 16 Sept
⏰8-9 AM UTC / 9-10 AM BST / 6-7 PM AEST
📍Online, download the calendar invite here: healtheconomics.org/event/applyi...

Applying Mendelian Randomization in Health Economics – Bridging Genomics and Cost-Effectiveness – International Health Economics Association

healtheconomics.org

1 5 4

Reposted by Economics of Genomics and Precision Medicine Unit

IHEA Econ-Omics SIG @ihea-econ-omics.bsky.social · Aug 19

(1/4) INVITATION: Webinar exploring distributional cost-effectiveness analysis (#DCEA) for advancing #healthequity

🗓️ Date & time: 6-7pm Wed 8 Oct EDT / 10-11pm Wed 8 Oct UTC / 9-10am Thurs 9 Oct AEDT
📍 Online, download the calendar invitation here: healtheconomics.org/event/advanc...

Advancing Health Equity through Distributional Cost-Effectiveness Analysis (DCEA) – International Health Economics Association

healtheconomics.org

1 1 4

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Jun 10

📢 New publication in The European Journal of Health Economics!

The paper assesses the psychometric performance CHU9D proxy version compared with the PedsQL in Australian children aged 0–7 years with congenital colorectal conditions.

Read our findings: link.springer.com/article/10.1...

Psychometric comparison of CHU9D and PedsQL 4.0 proxy version administered to parents of children with congenital colorectal conditions in Australia - The European Journal of Health Economics

Objective To assess the psychometric performance of the Child Health Utility (CHU9D) proxy version compared with the Pediatric Quality of Life Inventory (PedsQL) in Australian children aged 0–7 years ...

link.springer.com

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Jun 1

Recently our team conducted two #DCEs as part of the BabyScreen+ program to elicit the Australian public’s preferences, values, and priorities for genomic newborn screening (gNBS) and its implementation.

Read more here: sciencedirect.com/science/arti...

1 1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · May 9

Excited to welcome Thuy Dung (“Dzung”) Nguyen as our new Research Assistant in the Economics of Genomics and Precision Medicine Unit! Dzung will be contributing to a project evaluating the cost-effectiveness of genomic testing for children/adults with suspected kidney disease.

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 10

📄 pubmed.ncbi.nlm.nih.gov/38459833/
📄 pubmed.ncbi.nlm.nih.gov/39725011/
humgenomics.biomedcentral.com/articles/10....

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 10

📄 pubmed.ncbi.nlm.nih.gov/35181209/
📄 nature.com/articles/s41...
📄 pubmed.ncbi.nlm.nih.gov/34099885/
📄 pubmed.ncbi.nlm.nih.gov/37489581/
📄 pubmed.ncbi.nlm.nih.gov/40172779/

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 10

Links to the papers referenced in the presentation are included below.
📄 pubmed.ncbi.nlm.nih.gov/32266555/
📄 pubmed.ncbi.nlm.nih.gov/39522058/
📄 pubmed.ncbi.nlm.nih.gov/32024983/
📄 pubmed.ncbi.nlm.nih.gov/32371919/
📄 nature.com/articles/s41...
📄 pubmed.ncbi.nlm.nih.gov/32839572/

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 10

A few weeks ago, @iliasgoranitis.bsky.social
presented at the Pan American Health Organisation webinar series. The webinar explored the challenges and opportunities of incorporating genomic innovations into health systems. youtube.com/watch?v=cPQr...

Genomics in public health: Technology assessment

YouTube video by PAHO TV

youtube.com

1 2 6

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 3

Read more here: link.springer.com/article/10.1...

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 3

This systematic review highlights where genomic medicine is likely cost-effective across the cancer care continuum, from:
🔹 Prevention & early detection
🔹 Diagnosis, staging & planning
🔹 Treatment
🔹 Managing refractory/relapsed disease
🔹 Palliative & end-of-life care

1 1 2

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Apr 3

🔬 Excited to share our latest work: "The Cost Effectiveness of Genomic Medicine in Cancer Control", in collaboration with Cancer Australia and @who.int.

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 31

Preferences like testing uptake, treatment adherence, and trust in the healthcare system are key to evaluating genomic medicine. Ignoring them can bias cost-effectiveness and policy relevance.

🔎 Read the paper our team supported: rdcu.be/eaJBy

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 31

How has publicly funded genetic and genomic tests been used in Australia? Read our recent study on test utilisation and MBS funding here: www.nature.com/articles/s41...

Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023 - European Journal of Human Genetics

European Journal of Human Genetics - Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023

www.nature.com

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 28

Using #MCDA, we elicited expert preference values for the diagnostic, clinical, family, economic, and societal components of genomic utility. This enabled the development of a scoring system ranging from 0% to 100%. The utility indicators used in the scale are shown in the table.

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 28

Our team recently developed the Genomic Utility Valuation scale (#GUVscale), which systematically collects and weights key genomic outcomes to inform research, healthcare decision-making, and reimbursement priorities.

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 28

Our team is proud to have led the health economics component of the evidence review that informed this Framework.

Read our evidence review: canceraustralia.gov.au/sites/defaul...

canceraustralia.gov.au

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 28

Cancer Australia recently launched the National Framework for Genomics in Cancer Control, a major step toward integrating genomics into routine cancer care for all Australians.

Read the Framework: canceraustralia.gov.au/key-initiati...

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 26

Our recent micro-costing paper found that proteomics offers a more cost-effective solution with broader applications compared to respiratory chain enzymology for mitochondrial disorders in Australia. Read more of our findings here: ojrd.biomedcentral.com/articles/10....

Proteomics costs AU$897 (USD $607) per patient, outperforming traditional methods like respiratory chain enzymology in detecting mitochondrial and other rare diseases.

1

Economics of Genomics and Precision Medicine Unit @eigen-uom.bsky.social · Mar 26

Exciting research in #genomic_newborn_screening (gNBS)! Ilias and Riccarda contributed to this paper exploring public perspectives on which conditions should be included in #gNBS. Read more here: link.springer.com/article/10.1...

https://link.springer.com/article/10.1186/s40246-024-00611-x"